A Phase 2 interventional study of Sodium bicarbonate and sodium fluoride and Sodium fluoride in Oral Hygiene, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-31.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will compare the Gingival Bleeding and Gingival Inflammation following twice daily use of a sodium bicarbonate experimental dentifrice compared to a 0% sodium bicarbonate toothpaste after 24 weeks of use. The study will be conducted at Salus Research, Inc. Participants will be recruited from their database and by use of an external recruitment agency
This study will be a single-centre, examiner blind, two treatment, parallel group, stratified (by baseline number of bleeding sites smoking status and bacterial sampling) randomized clinical study. At the screening visit, following provision of written informed consent, eligible participants will be provided with a standard toothpaste and toothbrush for brushing once in at the clinic and for approximately one week use at home until the baseline visit. Participants will be asked to abstain from brushing over a 12 hour period prior to the Baseline visit. At the baseline visit an oral soft tissue (OST) assessment, Modified Gingival Index (MGI) and Bleeding Index (BI), and then dental plaque assessment will be performed. Participants will be stratified according to their baseline number of bleeding sites, smoking status and whether selected for bacterial sampling. Participants will be then randomized into one of two treatment groups. After using, their assigned treatment twice daily at home for 6 weeks (visit 3), 12 weeks (visit 4) and 24 weeks (visit 5), participants will return to the site with overnight plaque at approximately the same time of day as the Baseline visit if possible. Participants will undergo a full OST examination and the recording of any Adverse Events (AEs). Participants will then undergo MGI, BI followed by dental plaque assessment. Microbiological samples will be collected on a subset of 50 participants (Determined by first 50 participants randomized).
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants were advised to brush their teeth with experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
Drug: Sodium bicarbonate and sodium fluoride
Participants were advised to brush their teeth with reference dentifrice containing 1100ppm fluoride as sodium fluoride
Drug: Sodium fluoride
Drug pages: Sodium Bicarbonate · Sodium Fluoride
Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
Number of Gingival Bleeding Sites at 24 Weeks
The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
Time frame: 24 weeks
Modified Gingival Index (MGI) at 24 Weeks
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Time frame: 24 weeks
Number of Gingival Bleeding Sites at 6 and 12 Weeks
BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
Time frame: Baseline, 6 and 12 weeks
Modified Gingival Index (MGI)) at 6 and 12 Weeks.
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
Time frame: 6 and 12 weeks
Bleeding Index (BI) at 6, 12 and 24 Weeks
BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
Time frame: 6, 12 and 24 weeks
Plaque Control (Overall and Interproximal Dental Plaque Scores) at 6, 12 and 24 Weeks.
The dental examiner had used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. Interproximal Dental Plaque Scores were analyzed in the same way as for Overall scores but just based on mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth.
Time frame: 6, 12 and 24 weeks
Bacterial Count at Baseline, After 6, 12, 24 and 32 Weeks
Microbiological samples were collected at baseline, 6 weeks, 12 weeks, 24 weeks and 32 weeks. Plaque was harvested from contra-lateral 1st molar teeth, where no restorations are present, using a sterile paper point. The paper point was immersed into 4 ml of Calgon Ringer's solution in a sterile bijou and kept on ice until they can be taken to the laboratory for processing (within 24 hours).
Time frame: Baseline, 6, 12, 24 and 32 weeks
The participants were recruited at a clinical site in the USA.
| Milestone | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| Started | 123 | 123 |
| Completed | 107 | 109 |
| Not completed | 16 | 14 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Lost to follow-up | 6 | 7 |
| Withdrew: Protocol violation | 1 | 1 |
| Withdrew: Withdrawal by subject | 8 | 4 |
| Withdrew: Positive urine pregnancy test | 0 | 1 |
The Bleeding Index was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1 millimetre (mm) into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
| Number of bleeding sites | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| Number of Gingival Bleeding Sites at 24 Weeks | 13.24 ± 7.663 | 24.90 ± 9.044 |
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
| Units on a scale | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| Modified Gingival Index (MGI) at 24 Weeks | 1.26 ± 0.505 | 1.93 ± 0.408 |
BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
| Number of bleeding sites | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| Number of Bleeding Sites at Baseline | 29.76 ± 8.238 | 29.05 ± 8.390 |
| Number of Bleeding Sites at 6 weeks | 12.26 ± 9.339 | 23.23 ± 10.993 |
| Number of Bleeding Sites at 12 weeks | 15.73 ± 7.632 | 23.86 ± 9.265 |
MGI was assessed on facial and lingual surfaces at two sites on each tooth (papillae and margin). The scoring of the MGI was performed under dental office conditions using a standard dental light for illuminating the oral cavity. Compressed air, water and mouth mirrors were available to each examiner. This procedure was performed by a single examiner. The MGI scoring system is as follows: 0 = absence of inflammation; 1 = mild inflammation; slight change in color, little change in color; little change in texture of any portion of the marginal or papillary gingival unit; 2 = mild inflammation; criteria as above but involving the entire marginal or papillar gingival units; 3= moderate inflammation; glazing, redness, edema, and/ or hypertrophy of the marginal or papillary gingival unit; 4 = severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration
| Units on a scale | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| MGI at 6 weeks | 1.50 ± 0.567 | 1.96 ± 0.427 |
| MGI at 12 weeks | 1.50 ± 0.536 | 1.94 ± 0.464 |
BI was performed by a single examiner using a color coded periodontal probe. The probe was engaged approximately 1mm into the gingival crevice. A moderate pressure was used whilst sweeping from interproximal to interproximal along the sulcular epithelium. The BI scoring system used is as follows: 0= No bleeding after 30 seconds; 1= Bleeding upon probing after 30 seconds; 2= Immediate bleeding observed
| Units on a Scale | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| BI Score Score at 6 weeks | 0.15 ± 0.133 | 0.30 ± 0.172 |
| BI Score Score at 12 weeks | 0.19 ± 0.112 | 0.28 ± 0.135 |
| BI Score Score at 24 weeks | 0.17 ± 0.116 | 0.31 ± 0.159 |
The dental examiner had used the Turesky Modification of the Quigley Hein Index to assess plaque on all gradable teeth. Interproximal Dental Plaque Scores were analyzed in the same way as for Overall scores but just based on mesiofacial, facial, distofacial, mesiolingual, lingual and distolingual surfaces. Dental Plaque (Quigley-Hein, Turesky Modification Index) Units on a scale 0 to 5: 0= No plaque; 1= Slight flecks of plaque at the cervical margin of the tooth; 2= A thin continuous band of plaque (1 mm or smaller) at the cervical margin of the tooth; 3= A band of plaque wider than 1 mm but covering less than 1/3 of the crown of the tooth; 4= Plaque covering at least 1/3 but less than 2/3 of the crown of the tooth; 5= Plaque covering 2/3 or more of the crown of the tooth.
| Units on a scale | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| Overall Plaque Score at 6 weeks | 2.56 ± 0.536 | 3.01 ± 0.411 |
| Overall Plaque Score at 12 weeks | 2.54 ± 0.495 | 2.90 ± 0.374 |
| Overall Plaque Score at 24 weeks | 2.47 ± 0.437 | 2.92 ± 0.399 |
| Interproximal Plaque Score at 6 weeks | 2.78 ± 0.492 | 3.19 ± 0.351 |
| Interproximal Plaque Score at 12 weeks | 2.76 ± 0.437 | 3.10 ± 0.311 |
| Interproximal Plaque Score at 24 weeks | 2.71 ± 0.390 | 3.11 ± 0.336 |
Microbiological samples were collected at baseline, 6 weeks, 12 weeks, 24 weeks and 32 weeks. Plaque was harvested from contra-lateral 1st molar teeth, where no restorations are present, using a sterile paper point. The paper point was immersed into 4 ml of Calgon Ringer's solution in a sterile bijou and kept on ice until they can be taken to the laboratory for processing (within 24 hours).
| colony forming units per sample | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| Staph Count at Baseline (n=24, 26) | 0.2 ± 0.82 | 0.2 ± 0.86 |
| Steph Count at 6 weeks (n=24, 26) | 0.1 ± 0.34 | 0 ± 0.20 |
| Steph Count at 12 weeks (n=24, 26) | 1.8 ± 7.10 | 3.2 ± 15.47 |
| Steph Count at 24 weeks (n=23, 25) | 0.6 ± 1.59 | 0.2 ± 0.37 |
| Steph Count at 32 weeks (n=21, 21) | 0.2 ± 0.51 | 0.1 ± 0.36 |
| Yeast Count at Baseline (n=24, 26) | 203.4 ± 842.28 | 647.8 ± 2958.78 |
| Yeast Count at 6 weeks (n=23, 26) | 287.3 ± 1014.31 | 784.3 ± 1796.75 |
| Yeast Count at 12 weeks (n=24, 25) | 668.9 ± 812.81 | 411.3 ± 906.19 |
| Yeast Count at 24 weeks (n=17, 22) | 1479.6 ± 1165.48 | 1522.3 ± 1008.13 |
| Yeast Count at 32 weeks (n= 14, 14) | 2743.5 ± 2505.75 | 1206.4 ± 1008.34 |
| Coliform count at Baseline (n= 24, 26) | 3.9 ± 8.82 | 3.8 ± 8.27 |
| Coliform count at 6 weeks (n= 24, 26) | 2.6 ± 6.72 | 5.7 ± 20.05 |
| Coliform count at 12 weeks (n= 24, 26) | 10.9 ± 14.65 | 26.9 ± 78.47 |
| Coliform count at 24 weeks (n=23, 25) | 8.1 ± 16.86 | 12.6 ± 19.24 |
| Coliform count at 32 weeks (n=21, 21) | 10.9 ± 16.17 | 17.8 ± 29.84 |
| E. Coli count at Baseline (n=24, 26) | 0 ± 0 | 0 ± 0.20 |
| E. Coli count at 6 weeks (n=24, 26) | 0.1 ± 0.28 | 0 ± 0.20 |
| E. Coli count at 12 weeks (n=24, 26) | 0.1 ± 0.28 | 0 ± 0 |
| E. Coli count at 24 weeks (n=23, 25) | 0.3 ± 1.25 | 0.2 ± 0.55 |
| E. Coli count at 32 weeks (n=21, 21) | 0.6 ± 1.29 | 0 ± 0.22 |
Collected over Adverse events were collected throughout the study from the start of the washout period, until five days following last treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sodium Bicarbonate and Sodium Fluoride Dentifrice | — | 0/123 (0%) | 17/123 (13.8%) |
| Sodium Fluoride Dentifrice | — | 0/123 (0%) | 14/123 (11.4%) |
| Event | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice |
|---|---|---|
| MOUTH INJURYInjury, poisoning and procedural complications | 4/123 | 0/123 |
| TRAUMATIC ULCERInjury, poisoning and procedural complications | 0/123 | 3/123 |
| Cellulitis OrbitalInfections and infestations | 2/123 | 0/123 |
| PneumoniaInfections and infestations | 2/123 | 0/123 |
| Lower Respiratory Tract InfectionInfections and infestations | 1/123 | 0/123 |
| Acute sinusitisInfections and infestations | 0/123 | 1/123 |
| GASTROENTERITISInfections and infestations | 1/123 | 0/123 |
| PHARYNGITISInfections and infestations | 0/123 | 1/123 |
| PHARYNGITIS STREPTOCOCCALInfections and infestations | 1/123 | 0/123 |
| PULPITIS DENTALInfections and infestations | 0/123 | 1/123 |
| Age, Continuous(Years) | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice | Total |
|---|---|---|---|
| Mean | 39.39 ± 14.284 | 37.77 ± 12.615 | 38.58 ± 13.473 |
| Sex: Female, Male(Participants) | Sodium Bicarbonate and Sodium Fluoride Dentifrice | Sodium Fluoride Dentifrice | Total |
|---|---|---|---|
| Female | 74 | 78 | 152 |
| Male | 49 | 45 | 94 |
Ran from Aug 2014 to primary completion in Feb 2015, 5 months.
Results were first posted in Jul 2016, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sodium Bicarbonate · Sodium Fluoride